siRNA vs. shRNA: similarities and differences
- PMID: 19389436
- DOI: 10.1016/j.addr.2009.04.004
siRNA vs. shRNA: similarities and differences
Abstract
RNA interference (RNAi) is a natural process through which expression of a targeted gene can be knocked down with high specificity and selectivity. Using available technology and bioinformatics investigators will soon be able to identify relevant bio molecular tumor network hubs as potential key targets for knockdown approaches. Methods of mediating the RNAi effect involve small interfering RNA (siRNA), short hairpin RNA (shRNA) and bi-functional shRNA. The simplicity of siRNA manufacturing and transient nature of the effect per dose are optimally suited for certain medical disorders (i.e. viral injections). However, using the endogenous processing machinery, optimized shRNA constructs allow for high potency and sustainable effects using low copy numbers resulting in less off-target effects, particularly if embedded in a miRNA scaffold. Bi-functional design may further enhance potency and safety of RNAi-based therapeutics. Remaining challenges include tumor selective delivery vehicles and more complete evaluation of the scope and scale of off-target effects. This review will compare siRNA, shRNA and bi-functional shRNA.
Similar articles
-
Nonviral vector-mediated RNA interference: its gene silencing characteristics and important factors to achieve RNAi-based gene therapy.Adv Drug Deliv Rev. 2009 Jul 25;61(9):760-6. doi: 10.1016/j.addr.2009.04.006. Epub 2009 Apr 20. Adv Drug Deliv Rev. 2009. PMID: 19386274 Review.
-
Comparative assessment of siRNA and shRNA off target effects: what is slowing clinical development.Cancer Gene Ther. 2009 Nov;16(11):807-9. doi: 10.1038/cgt.2009.53. Epub 2009 Aug 28. Cancer Gene Ther. 2009. PMID: 19713999 Review.
-
Transkingdom RNA interference (tkRNAi) as a new delivery tool for therapeutic RNA.Expert Opin Biol Ther. 2009 Dec;9(12):1533-42. doi: 10.1517/14712590903307354. Expert Opin Biol Ther. 2009. PMID: 19769540 Review.
-
Nonviral delivery vehicles for use in short hairpin RNA-based cancer therapies.Expert Rev Anticancer Ther. 2007 Mar;7(3):373-82. doi: 10.1586/14737140.7.3.373. Expert Rev Anticancer Ther. 2007. PMID: 17338656 Review.
-
Strategies for short hairpin RNA delivery in cancer gene therapy.Expert Opin Biol Ther. 2009 Nov;9(11):1357-68. doi: 10.1517/14712590903236843. Expert Opin Biol Ther. 2009. PMID: 19761417 Review.
Cited by
-
Systematic Review of Genetic Substrate Reduction Therapy in Lysosomal Storage Diseases: Opportunities, Challenges and Delivery Systems.BioDrugs. 2024 Sep;38(5):657-680. doi: 10.1007/s40259-024-00674-1. Epub 2024 Aug 23. BioDrugs. 2024. PMID: 39177875 Free PMC article.
-
Delivery Strategies of siRNA Therapeutics for Hair Loss Therapy.Int J Mol Sci. 2024 Jul 11;25(14):7612. doi: 10.3390/ijms25147612. Int J Mol Sci. 2024. PMID: 39062852 Free PMC article. Review.
-
Diagnostic lncRNA high expression for liver patients prognosis and medication guidance: a systematic review and meta-analysis.Front Pharmacol. 2024 Aug 15;15:1462512. doi: 10.3389/fphar.2024.1462512. eCollection 2024. Front Pharmacol. 2024. PMID: 39211780 Free PMC article.
-
Significance of Nuclear Factor-Kappa B (NF-κB) and Survivin in Breast Cancer and Their Association with Radiosensitivity and Prognosis.Breast Cancer (Dove Med Press). 2023 Mar 9;15:175-188. doi: 10.2147/BCTT.S399994. eCollection 2023. Breast Cancer (Dove Med Press). 2023. PMID: 36923396 Free PMC article.
-
Multiplexed shRNA-miRs as a candidate for anti HIV-1 therapy: strategies, challenges, and future potential.J Genet Eng Biotechnol. 2022 Dec 28;20(1):172. doi: 10.1186/s43141-022-00451-z. J Genet Eng Biotechnol. 2022. PMID: 36576612 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
